Inclusion Criteria:

1. Must sign an informed consent form.
2. Age ≥ 25 and ≤ 75 years and may be of either gender and any race.
3. At least a 3 month history of chronic, stable angina that is documented as triggered by physical effort, and is relieved by rest and/or nitroglycerin.
4. Documented symptomatic CCS Anginal Classification of III to IV despite use of optimal medical therapy as noted in inclusion criterion 11.
5. Pattern of CHD (coronary pathology) where percutaneous interventional therapy and/or CABG is not recommended by the treating cardiologist.
6. One/two/three vessel disease as evidenced either by an angiographic documentation of advanced atherosclerotic narrowing of a major epicardial coronary artery, or of diffuse type of CHD as evidenced by the appearance on coronary angiography of multiple stenoses, multiple atherosclerotic plaques, and/or peripheral occlusion(s) of coronary vessel(s) with and without a history of MIs.
7. Subjects are required to demonstrate a radionuclide or angiographically determined left ventricular ejection fraction (LVEF) ≥ 40%.
8. Pre-operative proof of reversible ischemia.
9. No evidence of proliferative retinopathy or significant non-proliferative retinopathy.
10. Subjects must be on optimal medical therapy for at least 2 months prior to entering the study, as documented by a medical history. This will include medical management, and subjects must enter the study on at least one of the following medications: beta-blockers, calcium entry blockers, ranolazine, or long-acting nitrates.
11. Exercise duration during the qualifying treadmill tests at Visit 1 and Visit 2 is ≥ 3 and ≤ 9 minutes on a modified Bruce protocol.
12. Exercise durations for the 2 qualifying treadmill tests at Visits 1 and 2 do not differ by more than 20% of the longer of the 2 times and do not differ by more than 60 seconds.
13. The primary reason for stopping the 2 qualifying treadmill tests at Visits 1 and 2 must be angina and/or a horizontal or down sloping ST-segment depression of ≥ 1 mm during exercise, compared to pre-exercise ST segment, when measured 80 ms from the J point.
14. A forced vital capacity (FVC) of ≥ 30% .
15. A negative pregnancy test in women of childbearing potential within 7 days of the catheterization procedure.
16. Female subjects must be post-menopausal or sterilized, or if she is of childbearing potential, she is not breast feeding and she has no intention to become pregnant during the course of the study, and she is using contraceptive drugs or devices.
17. Ability to complete the study in compliance with the protocol.

Exclusion Criteria

1. History of undergoing a CABG, PTCA or TMR or evidence of an acute MI in the last 3 months.
2. Subjects with malignancies or a history of malignancies (with the exception of basal cell carcinoma [BCC] of the skin) will be excluded from the study. Those subjects with a history of BCC are eligible for enrollment, and will be monitored by a qualified dermatologist every 8 weeks for a period of 6 months for evaluation of their skin condition. Subjects with existing BCC will be excluded from the study.
3. Evidence of concurrent clinically significant infection (e.g., elevated white blood cell [WBC] count > 13,000 x 109/L, temperature > 38.5°C), evidence of "common cold" or "flu".
4. Concomitant other structural heart disease, such as heart valve disease, congenital heart disease, etc. other than evidence of congestive heart failure that is directly related to past ischemic events.
5. Left ventricular thrombus (mobile or mural-based) as evidenced by ventriculogram or echocardiography.
6. Creatine kinase (CK) levels >3 x upper limit of normal (ULN).
7. Renal insufficiency requiring dialysis or laboratory evidence of a serum creatinine > 2.0 mg/dL.
8. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN.
9. History of coagulation disorders or abnormal prothrombin time (PT) or partial thromboplastin time (PTT) > 1.5 x ULN, thrombocytopenia (< 100,000/µl), or ongoing anticoagulant therapy (with the exception of aspirin, up to 80 mg/day).
10. History of blood cell diseases.
11. Poorly controlled insulin-dependent diabetes mellitus (HbA1c > 8%)
12. Pre-existing retinal disease, including proliferative retinopathy, severe nonproliferative retinopathy.
13. Use of any illicit recreational drugs within the past year.
14. A positive test result for human immunodeficiency virus (HIV) antibody.
15. Screening ECG results demonstrating recent evidence of transmural ischemia.

16. Clinically significant ECG abnormalities that interfere with ST-T wave analysis, e.g.:

    • QRS duration > 0.12 seconds.
    • QTc > 450 ms in males or > 460 ms in females.
    • High-grade atrioventricular (AV) block.
    • Left bundle branch block (LBBB).
    • Left ventricular hypertrophy (LVH) with secondary ST-T changes.
    • Frequent, recurrent, or sustained ventricular arrhythmia.
    • Resting ST segment depression > 1 mm (measured 80 ms beyond the J point) at baseline.
17. Subjects having a concomitant life-threatening disease in which their life expectancy is estimated to be less than 2 years.
18. Any condition which in the opinion of the investigator would interfere with the participant's ability to provide informed consent and comply with study instructions, possibly confound interpretation of study results, or endanger the participant if he took part in the trial.
19. Use of an investigational drug, device or product, or participation in a drug research study within a period of 30 days prior to receiving IMP.
20. Any subject with unstable angina.
21. Heart failure New York Heart Association (NYHA) Functional Class III or IV.
22. Uncontrolled hypertension precluding exercise testing and/or contributing to anginal severity (systolic blood pressure [SBP] > 200 mmHg or diastolic blood pressure [DBP] > 110 mmHg), or significant hypotension (SBP < 90 mmHg or DBP < 60 mmHg).
23. Subjects currently on External Counter Pulsation therapy or who have received this therapy within 3 months prior to the screening date.
24. Any mobility or pulmonary complication that impedes the subject's ability to perform an exercise stress test.
25. Total fasting serum cholesterol ≥ 200 mg/dL (if levels higher than 200 mg/dL, additional medical interventions can be initiated to bring levels below 200 mg/dL).
26. History of heparin-induced thrombocytopenia.
27. Subjects with a history of recurrent symptomatic atrial fibrillation.
28. Aortic valve replacement.
29. Medical history and physical examination displaying any evidence that catheterization is contraindicated.